Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Depreciation (2023 - 2025)

Kura Oncology (KURA) has disclosed Accumulated Depreciation for 3 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation fell 11.45% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 11.45% decrease, with the full-year FY2025 number at $2.9 million, down 11.45% from a year prior.
  • Accumulated Depreciation was $2.9 million for Q4 2025 at Kura Oncology, down from $3.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $3.7 million in Q2 2025 to a low of $1.8 million in Q1 2023.
  • A 3-year average of $2.7 million and a median of $2.7 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: surged 37.18% in 2024, then decreased 11.45% in 2025.
  • Kura Oncology's Accumulated Depreciation stood at $2.5 million in 2023, then soared by 33.56% to $3.3 million in 2024, then dropped by 11.45% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Accumulated Depreciation are $2.9 million (Q4 2025), $3.7 million (Q2 2025), and $3.3 million (Q4 2024).